8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): November 21, 2005

                           DUSA PHARMACEUTICALS, INC.
             (Exact name of registrant as specified in its charter)

        New Jersey                      0-19777                22-3103129
(State or other jurisdiction       (Commission File          (IRS Employer
     of incorporation)                 Number)            Identification Number)

                                 25 Upton Drive
                         Wilmington, Massachusetts 01887
          (Address of principal executive offices, including ZIP code)

                                 (978) 657-7500
              (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Securities Act (17
     CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))




Item 8.01 - Other Events.

DUSA Pharmaceuticals, Inc. ("DUSA") issued a press release on the morning of
November 21, 2005, attached to and made a part of this report as Exhibit 99,
announcing that it has filed lawsuits against physicians in California, Florida,
and Tennessee to prevent their continued use of versions of its Levulan(R) brand
of aminolevulinic acid HCl (ALA) produced by compounding pharmacies, for use in
DUSA's patented photodynamic therapy (PDT) treatment for actinic keratosis,
basal cell carcinoma, acne and other dermatological conditions.

Additionally, some doctors are also being sued for misuse of DUSA's trademarks
and for violations of the Latham Act for using the Levulan(R) brand name on
their web sites and promotional materials, but performing patient treatments
with ALA obtained from other sources.

Except for historical information, this report, including the attached exhibit,
contains certain forward-looking statements that involve known and unknown risk
and uncertainties, which may cause actual results to differ materially from any
future results, performance or achievements expressed or implied by the
statements made. These forward-looking statements relate to the company's
expectations regarding its relationships. Furthermore, the factors that may
cause differing results include the uncertainties of litigation, sufficient
funding, maintenance of our patent portfolio and other risks identified in
DUSA's SEC filings from time to time.

Item 9.01 - Financial Statement and Exhibits.

Item No.      Description
- --------      -----------
  99          Press Release, dated November 21, 2005



                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                             DUSA PHARMACEUTICALS, INC.


Dated: November 21, 2005                     By: /s/ D. Geoffrey Shulman
                                                 ------------------------------
                                                 D. Geoffrey Shulman, MD, FRCPC
                                                 Chairman of the Board and Chief
                                                 Executive Officer



                                  Exhibit Index

Item No.     Description
- --------     -----------
  99         Press Release, dated November 21, 2005

EX-99

                                                                      EXHIBIT 99


[LOGO OF DUSA]
INNOVATION IN PHOTODYNAMIC THERAPY

DUSA Pharmaceuticals, Inc.(R)
For Release at 8:00 a.m.

          DUSA PHARMACEUTICALS SUES PHYSICIANS FOR INFRINGEMENT OF ITS
                    LEVULAN(R) PHOTODYNAMIC THERAPY PATENTS

   Suits Charge Use of Compounded ALA for PDT Infringes DUSA's Patent Rights

WILMINGTON, MA (November 21, 2005) - DUSA Pharmaceuticals, Inc. (R) (NASDAQ NMS:
DUSA) announced today it has filed lawsuits against physicians in California,
Florida, and Tennessee to prevent their continued use of versions of its
Levulan(R) brand of aminolevulinic acid HCl (ALA) produced by compounding
pharmacies, for use in the company's patented photodynamic therapy (PDT)
treatment for actinic keratosis, basal cell carcinoma, acne and other
dermatological conditions.

The suits allege that ALA obtained from sources other that DUSA Pharmaceuticals
is being used by physicians for patient treatments that are covered under
patents exclusively licensed by DUSA, resulting in direct infringement of these
patent(s).  Additionally, some doctors are also being sued for misuse of DUSA's
trademarks and for violations of the Latham Act for using the Levulan(R) brand
name on their web sites and promotional materials, but performing patient
treatments with ALA obtained from other sources.

"DUSA has worked diligently to develop and obtain U.S. Food and Drug
Administration (FDA) marketing approval for Levulan(R)," said Robert Doman,
DUSA's President and Chief Operating Officer. "As an FDA approved manufacturer
of drugs and medical devices, DUSA must meet the FDA's high standards for
safety, efficacy, potency, stability, and purity for our products.  Unlike
compounded ALA, which has not been approved for marketing by the FDA, our
products have undergone years of extensive and expensive clinical testing and
evaluation to reach the dermatology marketplace.  Our state-of-the-art
manufacturing facility has also been built and maintained to FDA standards."

In 2004 and in early 2005, DUSA sued two compounding pharmacies, The Cosmetic
Pharmacy of Tucson, AZ, and the New England Compounding Center in Framingham,
MA, for violations of U.S. patent law.  The Cosmetic Pharmacy presented no
defense against the suit so a default judgment was entered by the court in
DUSA's favor.  The court also took the unusual step of awarding attorney fees to
DUSA.  The suit against the New England Compounding Center is still pending.
The lawsuits allege that these compounding pharmacies were promoting their
compounded ALA for use in DUSA's patented therapies and were therefore inducing
physicians to infringe DUSA's patents.

Doman continued, "Use of compounded ALA for our patented therapies is a
violation of DUSA's intellectual property rights.  Because DUSA's patents cover
uses of ALA, compounding pharmacies are putting physicians at legal risk by
offering it for sale and encouraging its use.  While we will continue to value
and protect the longstanding relationships that we have made with the
dermatology community and with our loyal

doctors who use DUSA's proprietary Levulan(R), as a business, DUSA must protect
its investment in its products and enforce its intellectual property rights
against those physicians who use compounded ALA."

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is a biopharmaceutical company engaged primarily in
the development of Levulan(R) Photodynamic Therapy (PDT) and Photodetection (PD)
for multiple medical indications, with its primary focus in dermatology. PDT and
PD utilize light-activated compounds such as Levulan(R) to induce a therapeutic
or detection effect. The Company maintains offices in Wilmington, MA, Valhalla,
NY, and Toronto, Ontario.

Except for historical information, this news release contains certain
forward-looking statements that involve known and unknown risk and
uncertainties, which may cause actual results to differ materially from any
future results, performance or achievements expressed or implied by the
statements made.  These forward-looking statements relate to the company's
expectations regarding its relationships.  Furthermore, the factors that may
cause differing results include the uncertainties of litigation, sufficient
funding, maintenance of our patent portfolio and other risks identified in
DUSA's SEC filings from time to time.

For further information contact:
Bob Doman, President & COO
Scott Lundahl, Vice President, Intellectual Property & Regulatory Affairs
Tel: 978.657.7500
or Shari Lovell, Director, Shareholder Services
Tel: 416.363.5059 Fax 416.363.6602 or visit www.dusapharma.com